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Background/Aim. Coronary artery ectasia (CAE) was thought of as a variant of atherosclerosis. C-reactive protein (CRP) which is
amongthemostsensitivemarkersofsystemicinﬂammation,andelevationofsystemicandlocallevelsofthisinﬂammatorymarker
which has been associated with an increased risk for cardiovascular disease in the obstructive coronary artery disease (O-CAD) are
well known, but little was known in CAE. The anti-inﬂammatory eﬀects of statins and the eﬀect of angiotensin-converting enzyme
(ACE) inhibitors on endothelial dysfunction are well established in atherosclerosis. The aim of the present study was to investigate
CRP level and its response to statin and ACE inhibitor treatment in CAE. Materials and method. We measured serum hs-CRP
level in 40 CAE (26 males, mean age: 56.32 ± 9 years) and 41 O-CAD (34 males, mean age: 57.19 ± 10 years) patients referred
for elective coronary angiography at baseline and after 3-month statin and ACE inhibitor treatment. Results. Plasma hs-CRP levels
were signiﬁcantly higher in CAE group than O-CAD group at baseline (2.68±66mg/L versus 1,64±64, resp., P<. 0001). Plasma
hs-CRPlevelssigniﬁcantlydecreasedfrombaseline3monthslaterintheCE(from2.68±0.66mg/Lto1.2±0.53mg/L,P<. 0001)as
wellasintheO-CADgroup(from1.64±0.64mg/Lto1.01±0.56mg/L,P<. 001).Conclusion.Wethinkthaths-CRPmeasurement
may be a good prognostic value in CAE patients as in stenotic ones. Further placebo-controlled studies are needed to evaluate the
clinical signiﬁcance of this decrease in hs-CRP.
Copyright © 2007 Yilmaz Ozbay et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Coronary artery ectasia (CAE) was deﬁned as localized or
diﬀuse dilation of ≥ 1.5 times normal adjacent segments of
vessels [1]. It is estimated that 50% coronary artery ecta-
sia is related to atherosclerosis, whereas 20%–30% of cases
may be due to congenital anomalies [2–4], and CAE was
found in the range of 1.2–4.9% in diﬀerent series [1, 5].
Markisetal.revealedthattheunderlyinghistologicalchanges
were identical to those found in atherosclerotic lesions (dif-
fuse hyalinization, intimal, and medial damages) [6]. How-
ever, it is not known clear why some patients with obstruc-
tive coronary artery disease develop CAE, whereas most do
not. CRP is a sensitive marker of systemic inﬂammation [7].
The elevation of systemic and local levels of this inﬂamma-
tory marker has been associated with an increased risk for
cardiovascular disease [8]. Although the CRP in obstruc-
tive coronary artery disease (O-CAD) is well known, lim-
iteddataareavailableinCAEandthereareconﬂictingresults
[9, 10].
Accordingly, in this study we compared the plasma
hs-CRP levels in patients with isolated CAE and O-CAD
and their responses to statin (simvastatin 40mg/day) and
angiotensin-converting enzyme (ACE) inhibitor (perindo-
pril 8mg/day) treatment.
2. MATERIALS AND METHODS
2.1. Patients
This study was conducted between January 2005 and De-
cember 2005. The study population was selected from 2174
consecutive patients who underwent coronary angiography
in our clinic. The ﬁrst group consisted of 40 patients (CAE
group, 26 males, mean age: 56.32 ± 9 years) with isolated
CAE without signiﬁcant stenosis. These patients were se-
lected from individuals referred for coronary angiography
due to the presence of typical angina and/or abnormal non-
invasive test results suggesting myocardial ischemia. A to-
tal 53 (2.43%) CAE patients were found and 13 of them2 Mediators of Inﬂammation
were excluded from the study due to ACE inhibitor or statin
therapy. A well-matched control group (41 patients, O-CAD
group, 34 males, mean age: 57.19 ± 10 years) was selected
from patients referred for elective coronary angiography due
to presence of typical angina and/or abnormal noninvasive
test results suggesting myocardial ischemia and subsequently
was found to have signiﬁcant coronary artery stenosis, and
any revascularization was not planned before ﬁrst blood
sample was obtained. The local ethics committee approved
the study protocol. Written informed consent was obtained
prior to enrolment.
Those patients with collagen vascular disease, active in-
ﬂammation, acute coronary syndrome history, under ACE
inhibitorandstatintreatmentwerenotincludedinthestudy.
2.2. Coronaryangiogramsandimmunoassay
The coronary angiograms were performed by Judkin’s tech-
nique in multiple projections without the use of nitroglyc-
erine. Ultravist 370 (Schering AG, Germany) was used as the
contrastagentinallpatients.Twoexperiencedinvasivecardi-
ologists who were blinded to patients’ informations and lab-
oratory results evaluated the angiographies of patients. CAE
was considered when a vessel diameter was ≥ 1.5 times that
of adjacent normal segment. If no adjacent normal segment
could be identiﬁed, the mean diameters of the normal coro-
nary segments in stenotic patients served as normal values. A
signiﬁcant stenosis was deﬁned as a ≥ 50% loss of the diam-
eter near to adjacent normal segment.
Blood samples of all individual were taken 24 hours af-
ter coronary angiography from an antecubital vein. Blood
samples were centrifuged immediately at 250g for 10 min-
utes and stored at +4◦C until assay. The hs-CRP assayments
were done by Dade Behring BN II (Germany).
After blood sample was collected, simvastatin (40mg
daily) and perindopril (8mg daily) were added to the ther-
apy of all individuals. A second blood sample was collected
from all individuals by the same method 3 months later.
2.3. Statisticalanalyses
All data were analyzed by SPSS software (Statistical Pack-
age for the Social Sciences), version 12.0 for Windows. Data
were presented as mean ± standard deviation unless noted
as diﬀerent. Comparisons between groups were analyzed us-
ing the nonparametric Mann-Whitney U test. The relation-
ship between the number of vessel involvements and hs-CRP
was determined by linear regression analyses. Basal and 3-
monthhs-CRPlevelswithrespecttonumberofinvolvedves-
sels were determined by Spearman’s correlation. P value of
<. 05 was considered statistically signiﬁcant.
3. RESULTS
Baseline clinical characteristics of the two groups were sim-
ilar (Table 1). The angiographic characteristics of CAE were
presented in Table 2. Serum hs-CRP levels were signiﬁcantly
higher in CAE group than O-CAD group at baseline (2.68 ±
Table 1: Baseline clinical characteristics of the patients. CAE de-
notes coronary ectasia and O-CAD denotes obstructive coronary
artery disease.
CAE O-CAD
(n = 40) (n = 41)
Age (mean±SD) (years) 57.19±10 56.32±9
Sex (men) 32 34
Diabetes mellitus 21 26
Hypertension 18 13
LDL-cholesterol (mg/dL) 115 121
Smoking 17 12
Family history 25 24
Aspirin 40 (100%) 41 (100%)
Nitrate 31 (77.5%) 28 (68.29%)
Beta blockers 35 (87.5%) 36 (87.8%)
Table 2: Angiographic ﬁndings of ectasias.
Distribution of ectasia
Left anterior descending artery 20 (50%)
Circumﬂex 23 (57%)
Right coronary artery 24 (60%)
Number of involved vessels
1 17 (42,5%)
2 18 (45%)
3 5 (12.5%)
66mg/L versus 1,64±64, resp., P<. 0001) (Figure 1). Those
patients with multivessel involvement of CAE or O-CAD
had higher serum hs-CRP levels than single involvement
(P<. 001, 95%Cl; 0.285–0.625, R2 = 0.263). There was no
signiﬁcant correlation between average diameter of CAE and
hs-CRP (r = 0.244, P = .129), and a weak correlation
was observed between average ectasia diameter and hyper-
tension (HT) (r = 0.300, P = .06). However there was
a positive correlation between hs-CRP and length of ecta-
sia (r = 0.332, P = .037). A positive correlation was ob-
served between smoking and hs-CRP in O-CAD and CAE
(r = 0.430, P = .005; r = 0.587, P<. 0001, resp.). When hs-
CRP was analyzed with respect to age, a positive correlation
was found in O-CAD group and no correlation was found in
CAEgroup(r = 0.401,P = .09;r = 0.173,P = .287).Aposi-
tive correlation was observed between hs-CRP and LDL-C in
both CAE and O-CAD groups (r = 354, P = .001; r = 0.280,
P = .011, resp.). There was a positive correlation between
hs-CRP and diabetes mellitus (DM) (r = 0.473, P = .002)
but no correlation with HT in O-CAD group (r = 0.087,
P = .590). However, there was no correlation between hs-
CRP and DM and HT in CAE group (r = 0.681, P = .067;
r = 0.673, P = .069).
Serum hs-CRP levels signiﬁcantly decreased from base-
line 3 months later in the CAE (from 2.68 ± 0.66mg/L to
1.2 ± 0.53mg/L, P<. 0001) as well as in the O-CAD group
(from 1.64 ± 0.64mg/L to 1.01 ± 0.56mg/L, P<. 001).
However, the quantitative and proportional reduction wasYilmaz Ozbay et al. 3
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CAE: coronary ectasia
O-CAD: obstructive coronary artery disease
Figure 1: The hs-CRP levels in both groups at baseline and third
month.
Table 3: hs-CRP Levels (mg/L) and number of vessel involve-
ments. CAE denotes coronary ectasia and O-CAD denotes obstruc-
tive coronary artery disease.
Number of vessel
involvements
CAE O-CAD
(n = 40) (n = 41)
Basal 3 months Basal 3 months
Single 2.20 (17) 1.16 1.03 (17) 0.95
Multiple 3.03 (23) 1.24 1.93 (24) 1.04
signiﬁcantlyhigherintheCAEgroupthantheO-CADgroup
(68% versus 45% (P<. 001)). Most signiﬁcant decreases in
hs-CRP were observed in patients with higher baseline hs-
CRP levels (P<. 1, R2 = 0.617) (Table 3). The hs-CRP lev-
els became similar after 3-month treatment (1.2±0.53mg/L
in CAE versus 1.01 ± 0.56mg/L in O-CAD group, P>. 05)
(Figure 1).
4. DISCUSSION
CAE was found in the range of 1.2%–4.9% in diﬀerent series
[5, 6]. It causes adverse coronary events like vasospasm, dis-
section, and thrombosis [5]. There is still controversy about
the pathogenetic mechanism that underlies this entity. It is
estimated that 50% of CAE is related to atherosclerosis and
others are related to congenital or inﬂammatory disease like
Kawasaki syndrome. Extensive structural damage was ob-
served in diﬀerent layers of vessel especially in the tunica me-
dia and intima in histological examinations [5, 11].
Inﬂammatory process begins from the earliest phase
of atherosclerosis, formation of fatty streak, involving the
leukocytes inﬁltration and link between plaque formation
and acute plaque rupture, leading to acute coronary syn-
dromes[12].Theacute-phasereactant,CRP,asimplemarker
of inﬂammation, has now emerged as a major cardiovascu-
lar risk factor [13]. High-sensitive CRP (hs-CRP) was shown
to be an independent risk factor for MI, stroke, sudden
death, and peripheral arterial disease in diﬀerent prospec-
tiveepidemiologicalstudiesanditcanbedecreasedbystatins
independent of the LDL-level reductions [14–16]. It was
shown that angiotensin II induces inﬂammatory changes in
human vascular smooth muscle cells; and in animal models
of atherosclerosis, this inﬂammation was suppressed by ACE
inhibitors [17, 18]. Tsikouris et al. reported that quinapril
(higher tissue penetration than enalapril) had stronger eﬀect
onhs-CRPreductionthanenalaprilfollowingmyocardialin-
farction [19]. And in the EUROPA study, beneﬁcial eﬀect of
perindopril on future cardiovascular events in stable angina
patients was shown [20].
Althoughlargebodyofinformationabouttheinﬂamma-
tory process underlying the O-CAD is present, limited data
are available about the role of inﬂammation in the pathogen-
esis of CAE.
In this study, we found signiﬁcantly higher levels of hs-
CRP in CAE when compared to O-CAD. Turhan et al. found
similar results with our ﬁndings, whereas Finkelstein found
that hs-CRP levels were similar in both CAE and O-CAD
[9,10].Wethinkthatthisconﬂictingresultmaybeduetothe
study population. Most of the patients in Finkelstein study
were using statins or ACE inhibitors at the beginning of the
study (82.3%, 52.9%, resp.) and these agents might suppress
the inﬂammatory process. Besides these ﬁndings, extensive
inﬂammation including medial and adventitial cell inﬁltra-
tions was observed in postmortem examination of aortic
aneurysm, and higher serum CRP levels were observed in
asymptomatic aortic aneurysm persons [21, 22]. We suggest
that this extensive inﬂammation is responsible for higher hs-
CRP levels in CAE. We have shown that this higher hs-CRP
level responded to statin and ACE inhibitor treatment dra-
matically and again signiﬁcant reduction was observed in O-
CAD group and hs-CRP levels meet the same level at the end
of 3-month treatment. We believe that the suppression of the
inﬂammation may prevent adverse coronary events in CAE.
In multivariable analysis, hs-CRP was found signiﬁcantly
correlated with smoking, LDL-C, and a weak correlation be-
tween HT and ectasia diameter, but no correlation was ob-
served between hs-CRP and age and DM in CAE group,
whereas a signiﬁcant correlation was found with respect to
age, DM, smoking, LDL-C in O-CAD group. In previous
studies, smoking was represented as a risk factor for CAE
[23, 24]. We think that smoking seems to induce adverse
events in CAE beside its eﬀect on pathogenesis of CAE. The
ﬁnding of any correlation between hs-CRP and age in CAE
group is correlated with the previous report of CAE seen in
younger-age group [25]. In a large- scale study; Androulakis
etal.reportedaninverserelationbetweenCAEandDM[26].
In our study, we choose patients with similar risk factor pro-
ﬁles in both groups, so we did not have chance to reach such
a conclusion, but in our CAE group no correlation was ob-
served between hs-CRP and DM supporting this ﬁnding.
In conclusion, we found that hs-CRP levels were signiﬁ-
cantly higher in CAE patients than O-CAD. And this higher
inﬂammatory process responded to statin and ACE inhibitor
therapydramaticallyattheendof3-monththerapy.Wethink4 Mediators of Inﬂammation
thaths-CRPmeasurementmaybeagoodprognosticvaluein
CAE patients as in stenotic ones. Further placebo-controlled
studies are needed to evaluate the clinical signiﬁcance of this
decrease in hs-CRP.
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